Regulatory Considerations for Structured Products

In March 2025, a FINRA arbitration panel handed the Jannetti family $132.5 million -- the largest retail arbitration award in FINRA history -- after a structured note strategy at Stifel Financial went catastrophically wrong. That same year, the SEC's enforcement actions hit a decade-low, and US structured product issuance surged to $149.4 billion. The collision of record volume, lighter oversight, and mounting investor losses creates a regulatory environment you need to understand before a single dollar goes into these instruments. The point is: regulation isn't background noise here -- it's the architecture that determines whether you get a fair deal or become the next cautionary tale.

Why the Regulatory Landscape Matters More Than You Think

Structured products sit at the intersection of securities law, derivatives regulation, and investor protection rules -- and no single framework covers all of it. The product you're evaluating might be registered with the SEC as a debt security, governed by FINRA suitability rules at the distribution level, and simultaneously subject to EU disclosure requirements if it's offered cross-border. Miss any layer and you're flying blind.

Here's the practical chain of risk:

Regulatory gap (cause) --> Inadequate disclosure (mechanism) --> Mispriced risk (investor experience) --> Concentrated losses (outcome)

That chain played out with devastating precision in the GWG Holdings collapse (more on that below), and it repeats in smaller ways every time a product slips through regulatory cracks. Why this matters: the rules aren't just compliance overhead -- they're your early warning system for products that shouldn't exist in your portfolio.

Reg BI Is Now a Live Weapon (Not Just a Compliance Checkbox)

When Regulation Best Interest took effect in June 2020, skeptics called it "suitability-plus" -- a marginal upgrade over the old FINRA suitability standard. Six years later, the enforcement trajectory tells a different story.

The SEC charged Western International Securities and five individual brokers with violating Reg BI after the firm sold $13.3 million in GWG Holdings L Bonds to retail customers -- many on fixed incomes with moderate risk tolerances. The issuer itself had described the bonds as "high risk, illiquid, and only suitable for customers with substantial financial resources." Western sold them anyway.

The SEC found violations of both the Care Obligation (no reasonable diligence on risks, rewards, and costs) and the Compliance Obligation (inadequate written policies). The settlement: disgorgement of $34,468 plus a $160,000 civil penalty from the SEC, and a separate $475,000 FINRA fine with over $1 million in restitution for supervisory failures.

The point is: this wasn't some ambiguous gray area. The issuer's own documents said the product was unsuitable for the customers who bought it, and the brokers recommended it anyway. Reg BI turned that from a "he said, she said" suitability dispute into a clear enforcement action.

The enforcement ramp has been steep (and deliberate):

• 2021: 2 Reg BI actions
• 2022: 8 actions
• 2023: Over 20 actions
• 2024-2025: Over 40 cumulative actions since 2023; FINRA has settled over 30 cases since inception

A critical shift you should notice: regulators are now fining individual brokers, not just firms. That's a departure from past enforcement patterns and it changes the incentive structure entirely. Your broker now has personal liability skin in the game (which theoretically makes recommendations more careful, but also means firms may restrict product access rather than invest in compliance infrastructure).

Why this matters: if you're buying structured products through a broker-dealer, Reg BI gives you concrete grounds for recovery if the recommendation was unsuitable. But you have to understand what "suitable" means for your profile -- because the broker's documentation of that analysis is now a regulatory requirement, and you're entitled to see it.

When Products Blow Up (Case Studies in Regulatory Failure)

GWG Holdings L Bonds: $1.6 Billion, 26,000 Investors, 3 Cents on the Dollar

GWG Holdings sold $1.6 billion in "L Bonds" -- debt instruments backed by life insurance policy pools -- to approximately 26,000 investors, many of them retirees. The bonds defaulted on a $3.25 million interest payment in January 2022. GWG filed Chapter 11 in April 2022.

The recovery? The current settlement offers approximately $31.48 per $1,000 of face value -- roughly 3 cents on the dollar. The GWG Wind Down Trust estimates final recovery at 2.7-3.45%, with no distributions expected until 2026 at the earliest.

The rule that survives: the SEC investigation (subpoenas started in late 2020) actually contributed to the collapse by scaring off new bond sales -- which exposed what analysts described as a Ponzi-like dependence on new capital to pay existing obligations. The regulatory system caught it, but not before $1.6 billion in retail money was already in.

SVB Autocallable Notes: Worthless Before Settlement

Five autocallable notes were issued tied to Silicon Valley Bank stock between August 2021 and March 2023. Here's the detail that should make you pause: Citigroup issued an autocallable note on March 9, 2023 -- after SVB's stock had already suffered catastrophic declines, and one day before the FDIC seized the bank. That note was completely worthless before it even settled.

Other results from the SVB-linked notes:

• Credit Suisse's note paid $1.70 per $1,000 at maturity
• RBC's note paid $2.50 in one quarterly coupon per $100 face value
• HSBC's note paid $11.15 in four quarterly coupons per $100 face value

The practical point: autocallable notes with knock-in barriers (typically set at 60-70% of initial price) expose you to dollar-for-dollar losses once the barrier is breached. The "conditional protection" language in the marketing materials sounds reassuring until it isn't. And the fact that a major issuer created a new note on a stock already in freefall should tell you everything about how these products get manufactured (hint: it's about issuer economics, not investor outcomes).

The Stifel Mega-Award: $180 Million and Counting

Beyond the headline $132.5 million arbitration award, Stifel had already paid almost $16 million in two other Roberts-related cases (including a $14.2 million award with $9 million in punitive damages), and settled four additional claims for almost $32 million. Total Roberts-related damages now exceed $180 million. FINRA subsequently barred Chuck Roberts from the industry rather than continue cooperating with the investigation.

The test: if your broker's structured product strategy relies on concentrated positions or aggressive allocations, ask yourself whether the expected return justifies the tail risk of outcomes like these. The Jannetti family eventually recovered -- but only after years of litigation and extraordinary legal costs.

The Hidden Cost Problem (What You're Actually Paying)

Structured products embed costs in ways that are genuinely difficult to detect, even for sophisticated investors. Here's what the data shows:

The Henderson and Pearson study (published in the Journal of Financial Economics) is the foundational work here. They analyzed 64 issues of a popular retail structured equity product and found that offering prices were almost 8% greater on average than fair market value estimates obtained using standard option pricing methods. The mean expected return on the structured products was slightly below zero.

The point is: you're not just paying for complexity -- you're paying a premium that, on average, pushes your expected return below what you'd earn from simpler alternatives. The 8% fair value gap means that on the day you buy, you're already underwater relative to what the embedded options are actually worth.

A specific example: Barclays' contingent coupon notes in 2024 carried an effective expense ratio of 2.3% per year for two-year terms. Compare that to an ETF tracking the same underlying index at 0.03-0.10% annually. The structured note needs to deliver meaningfully better risk-adjusted returns just to break even on costs -- and the data says most don't.

Why this matters: cost is the single most reliable predictor of investment outcomes over time. A 1.5-2% annual drag compounds into serious wealth destruction over a decade. Before evaluating payoff structures, barrier levels, or conditional coupons, calculate the all-in cost and compare it to simpler alternatives that deliver similar exposure.

The EU Disclosure Mess (And What the UK Is Doing About It)

The EU's PRIIPs Key Information Document was supposed to solve cost transparency for retail investors. It hasn't.

BETTER FINANCE tested the KID's performance forecast methodology against 138 years of S&P 500 data (1,662 rolling 5-year periods). Their findings: the methodology uses linear performance projections that don't embed the volatility inherent in capital markets. The "Moderate scenario" is presented without a prominent warning that it's not the most probable outcome -- but retail investors naturally assume it is. Even the European Supervisory Authorities themselves acknowledged that the performance scenario amendments "raise comprehension issues and may be misleading."

The UK saw the writing on the wall and decided to replace PRIIPs entirely. In December 2025, the FCA published Policy Statement PS25/20, finalizing the Consumer Composite Investments (CCI) framework:

• UK PRIIPs Regulation repealed April 6, 2026
• Transition period: April 2026 to June 2027 (firms choose KID or CCI)
• Full mandatory CCI regime: June 8, 2027
• Risk/return calculation shifts to a value-at-risk equivalent volatility (VEV) model
• Entire framework anchored to the FCA's Consumer Duty (not just disclosure rules)

The practical takeaway: if you're evaluating structured products with EU or UK exposure, the disclosure documents you receive over the next two years will be in flux. During the transition period (April 2026 to June 2027), you might see either format -- and the two frameworks calculate risk and performance differently. Don't assume comparability across documents from different jurisdictions.

Cross-Border Arbitrage (Where Products Go to Avoid Rules)

Here's a pattern you should understand: structured products can be domiciled in one jurisdiction, manufactured in another, and distributed in a third -- each with different regulatory requirements. The result is regulatory arbitrage that systematically weakens investor protections.

The Channel Islands play: Jersey and Guernsey offer lighter-touch regulation for structured products. A product issued from Jersey can access institutional capital through clearing systems or exchange listing without qualifying as a fund, avoiding PRIIPs KID requirements entirely when not sold to EEA retail investors. The catch (and it's a big one): products can be structured as nominally professional-only to avoid EU disclosure requirements, then distributed through wealth management channels where the professional/retail boundary is blurred.

The post-Brexit gap: The UK's decision to replace PRIIPs with CCI creates a new arbitrage dimension. During the transition, manufacturers can choose between the old PRIIPs KID and the new CCI product summary -- creating potential for forum-shopping between EU and UK disclosure regimes.

The US approach: FINRA's Regulatory Notice 22-08 (March 2022) addressed complex products but deliberately avoided creating a static definition of "complex product," construing the term flexibly instead. This contrasts with the EU's more prescriptive approach and creates different compliance burdens depending on where the product is distributed.

The core principle: if you can't identify which regulatory framework governs your structured product -- and what protections that framework provides -- you're taking on regulatory risk you haven't priced. The product might be perfectly legal in its jurisdiction of issuance while offering fewer protections than you'd expect from your home market.

Detection Signals (How to Spot Regulatory Red Flags)

You should be concerned about regulatory risk in a structured product if:

• The disclosure documents don't clearly state total embedded costs (not just "entry costs" but ongoing fees, structuring margins, and bid-ask spreads)
• The product is domiciled in a jurisdiction different from where you're buying it (and you can't explain why)
• Your broker can't articulate the Reg BI analysis that supports the recommendation for your specific profile
• The performance scenarios show only favorable or moderate outcomes without stress-testing against historical drawdowns
• The issuer's credit rating is below investment grade (or you don't know the issuer's credit rating -- a surprisingly common situation)
• The product documentation uses phrases like "principal protection" without specifying it's subject to issuer credit risk

Regulatory Protection Checklist (Tiered)

Essential (prevents 80% of regulatory-related losses)

These four actions cost nothing and take less than an hour:

• Verify SEC registration status -- confirm the product is filed under Form 424B2 (or understand why it isn't)
• Request the all-in cost breakdown in writing -- embedded fees, distribution fees, structuring margin, secondary market spread
• Ask your broker for the Reg BI documentation supporting the recommendation for your specific risk profile and financial situation
• Check the issuer's current credit rating at all three agencies (Moody's, S&P, Fitch) -- your principal depends on it

High-impact (systematic protection for active structured product investors)

For investors who allocate regularly to structured products:

• Compare the product's expected return against a simple portfolio delivering similar exposure (index ETF + Treasury allocation matching the product's risk profile)
• Calculate the fair value gap using publicly available option pricing data for the embedded derivatives
• Track FINRA enforcement actions quarterly at finra.org/rules-guidance/oversight-enforcement for products and issuers in your portfolio
• Verify which regulatory framework governs -- especially for cross-border products where disclosure standards may differ from your home jurisdiction

Optional (for investors with complex cross-border exposure)

If you hold structured products across multiple jurisdictions:

• Monitor the UK's PRIIPs-to-CCI transition for changes in risk calculation methodology that may reclassify product risk levels
• Review Channel Islands-domiciled products for professional-only classification that may limit your regulatory protections
• Track ESA Q&A updates on PRIIPs KID methodology (last updated May 2025) for changes affecting cost and performance disclosures

Next Step (Put This Into Practice)

Pull up the most recent structured product in your portfolio (or one you're considering) and run this three-question audit:

1. What are you actually paying? Request the full cost breakdown. Add embedded fees + distribution fees + structuring margin + estimated bid-ask spread. If the total exceeds 2% annually, you need a compelling reason why this product beats a simpler alternative delivering similar exposure at 0.10%.

2. Is the recommendation documented? Ask your broker or advisor for the written Reg BI analysis. If they can't produce it (or it doesn't address your specific risk tolerance and financial situation), that's a compliance failure -- and it's your leverage if the product underperforms.

3. Do you understand the issuer credit risk? Every structured note is an unsecured obligation of the issuer. If the issuer defaults, your "protected" principal disappears regardless of barrier levels or coupon structures. Check the rating. If it's below A-, understand why you're comfortable with that counterparty exposure.

Action: If any of these three questions produces an unsatisfying answer, that's your signal to pause before committing capital. The regulatory framework exists to protect you -- but only if you use it.